Trials / Completed
CompletedNCT04855617
Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclerosis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 122 (actual)
- Sponsor
- NYU Langone Health · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to determine whether symptom burden differs by time to infusion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ocrelizumab | Administer Ocrelizumab under the close supervision of an experienced healthcare professional with access to appropriate medical support to manage severe reactions such as serious infusion reactions. * Initial dose: 300 mg intravenous infusion, followed two weeks later by a second 300 mg intravenous infusion. * Subsequent doses: single 600 mg intravenous infusion every 6 months. * Observe the patient for at least one hour after the completion of the infusion |
Timeline
- Start date
- 2020-10-26
- Primary completion
- 2022-10-01
- Completion
- 2022-10-01
- First posted
- 2021-04-22
- Last updated
- 2023-06-15
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04855617. Inclusion in this directory is not an endorsement.